Psilocybin is a serotonergic psychedelic found in “magic mushrooms” with a putative therapeutic potential for treatment-resistant depression, anxiety, obsessive-compulsive disorder, and addiction. In rodents, psilocybin acutely induces plasticity-related immediate early genes in cortical tissue; however, studies into the effects on subcortical regions, of different doses, and the subsequent translation of corresponding proteins are lacking.
Methods:
We examined the acute effects of a single administration of psilocybin (0.5–20 mg/kg) on the expression of selected genes in the prefrontal cortex and hippocampus. In total, 46 target genes and eight reference genes were assessed using real-time quantitative polymerase chain reaction. Corresponding protein levels of the three most commonly regulated genes were assessed using Western blotting.
Results:
In the prefrontal cortex, psilocybin increased the expression of Cebpb, c-Fos, Dups1, Fosb, Junb, Iκβ-α, Nr4a1, P11, Psd95, and Sgk1, and decreased the expression of Clk1. In the hippocampus, psilocybin strongly increased the expression of Arrdc2, Dusp1, Iκβ-α, and Sgk1 in a dose-dependent manner, and decreased the expression of Arc, Clk1, Egr2, and Ptgs2. Protein levels of Sgk1, Dusp1, and Iκβ-α showed only partial agreement with transcriptional patterns, stressing the importance of assessing downstream translation when investigating rapid gene responses.
Conclusion:
The present study demonstrates that psilocybin rapidly induces gene expression related to neuroplasticity, biased towards the prefrontal cortex, compared to the hippocampus. Our findings provide further evidence for the rapid plasticity-promoting effects of psilocybin.
AghajanianGKMarekGJ (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res825: 161–171.
2.
AlberiniCM (2009) Transcription factors in long-term memory and synaptic plasticity. Physiol Rev89: 121–145.
3.
AlberiniCMGhirardiMMetzR, et al. (1994) C/EBP is an immediate-early gene required for the consolidation of long-term facilitation in Aplysia. Cell76: 1099–1114.
4.
AlmaulaNEbersoleBJBallesterosJA, et al. (1996) Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: Direct and indirect effects on ligand affinity mediated by the same locus. Mol Pharmacol50: 34–42.
5.
AnackerCCattaneoAMusaelyanK, et al. (2013) Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A110: 8708–8713.
6.
BeiqueJCImadMMladenovicL, et al. (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A104: 9870–9875.
7.
BeliveauVGanzMFengL, et al. (2017) A high-resolution in vivo atlas of the human brain’s serotonin system. J Neurosci37: 120–128.
8.
BenekareddyMNairARDiasBG, et al. (2013) Induction of the plasticity-associated immediate early gene Arc by stress and hallucinogens: Role of brain-derived neurotrophic factor. Int J Neuropsychopharmacol16: 405–415.
9.
BogenschutzMPForcehimesAAPommyJA, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
10.
BonefeldBEElfvingBWegenerG (2008) Reference genes for normalization: A study of rat brain tissue. Synapse62: 302–309.
11.
BramhamCRWorleyPFMooreMJ, et al. (2008) The immediate early gene Arc/Arg3.1: Regulation, mechanisms, and function. J Neurosci28: 11760–11767.
12.
BridiMSHawkJDChatterjeeS, et al. (2017) Pharmacological activators of the NR4A nuclear receptors enhance LTP in a CREB/CBP-dependent manner. Neuropsychopharmacology42: 1243–1253.
13.
Carhart-HarrisRLBolstridgeMDayCMJ, et al. (2018) Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl)235: 399–408.
14.
Carhart-HarrisRLBolstridgeMRuckerJ, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry3: 619–627.
15.
Carhart-HarrisRLRosemanLBolstridgeM, et al. (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep7: 13187.
16.
ContiBMaierRBarrAM, et al. (2007) Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry12: 167–189.
17.
DuricVBanasrMLicznerskiP, et al. (2010) A negative regulator of MAP kinase causes depressive behavior. Nat Med16: 1328–1332.
18.
El-HusseiniAESchnellEChetkovichDM, et al. (2000) PSD-95 involvement in maturation of excitatory synapses. Science290: 1364–1368.
19.
ErritzoeDRosemanLNourMM, et al. (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand138: 368–378.
20.
FicekJZygmuntMPiechotaM, et al. (2016) Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics17: 362.
21.
FriedelCCDolkenLRuzsicsZ, et al. (2009) Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Res37: e115.
22.
GallaherTKChenKShihJC (1993) Higher affinity for human than rat 5-HT2 receptor indicates binding site structure. Medicinal Chemistry Research3: 52–66.
23.
Gonzalez-MaesoJWeisstaubNVZhouM, et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron53: 439–452.
24.
Gonzalez-MaesoJYuenTEbersoleBJ, et al. (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci23: 8836–8843.
25.
GriffithsRRichardsWJohnsonM, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol22: 621–632.
26.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30: 1181–1197.
27.
GrobCSDanforthALChopraGS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
28.
HalberstadtALKoedoodLPowellSB, et al. (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol25: 1548–1561.
29.
HaydenMSGhoshS (2008) Shared principles in NF-kappaB signaling. Cell132: 344–362.
30.
HibickeMLandryANKramerHM, et al. (2020) Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci11: 864–871.
31.
HibickeMNicholsC (2020) One dose of psilocybin in late adolescence mitigates deleterious effects of developmental stress on cognition and behavioral despair in adult female rats. FASEB J34(Suppl 1): 1.
32.
JeanneteauFBarrereCVosM, et al. (2018) The stress-induced transcription factor NR4A1 adjusts mitochondrial function and synapse number in prefrontal cortex. J Neurosci38: 1335–1350.
33.
JeanneteauFDeinhardtKMiyoshiG, et al. (2010) The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. Nat Neurosci13: 1373–1379.
34.
JefsenOHojgaardKChristiansenSL, et al. (2019) Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta Neuropsychiatr. Epub ahead of print 21 May 2019. DOI: 10.1017/neu.2019.15.
35.
JohnsonMPBaezMKursarJD, et al. (1995) Species differences in 5-HT2A receptors: Cloned pig and rhesus monkey 5-HT2A receptors reveal conserved transmembrane homology to the human rather than rat sequence. Biochim Biophys Acta1236: 201–206.
36.
JohnsonMPLoncharichRJBaezM, et al. (1994) Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol45: 277–286.
37.
JohnsonMWGarcia-RomeuACosimanoMP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
38.
JohnsonMWGarcia-RomeuAGriffithsRR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse43: 55–60.
39.
KarakiSBecamelCMuratS, et al. (2014) Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol Cell Proteomics13: 1273–1285.
40.
KelleherRJ3rdGovindarajanATonegawaS (2004) Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron44: 59–73.
41.
KeyseSMEmslieEA (1992) Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature359: 644–647.
42.
KnapskaEKaczmarekL (2004) A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?Prog Neurobiol74: 183–211.
43.
KogaSKojimaSKishimotoT, et al. (2012) Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation. Brain Res1436: 137–146.
44.
KometerMSchmidtAJanckeL, et al. (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci33: 10544–10551.
45.
KovacsKJ (1998) c-Fos as a transcription factor: A stressful (re)view from a functional map. Neurochem Int33: 287–297.
46.
Kurrasch-OrbaughDMWattsVJBarkerEL, et al. (2003) Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther304: 229–237.
47.
LangFStrutz-SeebohmNSeebohmG, et al. (2010) Significance of SGK1 in the regulation of neuronal function. J Physiol588: 3349–3354.
48.
Lopez-GimenezJFGonzalez-MaesoJ (2018) Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci36: 45–73.
49.
LyCGrebACCameronLP, et al. (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep23: 3170–3182.
50.
MadsenMKFisherPMBurmesterD, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology44: 1328–1334.
51.
MartinDANicholsCD (2016) Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine11: 262–277.
52.
MattsonMPMeffertMK (2006) Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ13: 852–860.
53.
MeinhardtMWGüngörCSkorodumovI, et al. (2020) Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. Neuropsychopharmacology1–9.
54.
MithoeferMCGrobCSBrewertonTD (2016) Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. Lancet Psychiatry3: 481–488.
55.
MorenoFAWiegandCBTaitanoEK, et al. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry67: 1735–1740.
56.
NairABJacobS (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm7: 27–31.
57.
NicholsCDGarciaEESanders-BushE (2003) Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res111: 182–188.
58.
NicholsCDSanders-BushE (2002) A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology26: 634–642.
59.
NicholsCDSanders-BushE (2004) Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins. J Neurochem90: 576–584.
60.
PazosACortesRPalaciosJM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res346: 231–249.
61.
PazosAPalaciosJM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res346: 205–230.
62.
PriceJLDrevetsWC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology35: 192–216.
63.
RickliAMoningODHoenerMC, et al. (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol26: 1327–1337.
64.
RossSBossisAGussJ, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol30: 1165–1180.
65.
SchwanhausserBBusseDLiN, et al. (2011) Global quantification of mammalian gene expression control. Nature473: 337–342.
66.
SheldonPWAghajanianGK (1990) Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: Evidence for the involvement of a 5-HT2-activated interneuron. Brain Res506: 62–69.
67.
StuderusEKometerMHaslerF, et al. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol25: 1434–1452.
68.
SvenningssonPKimYWarner-SchmidtJ, et al. (2013) p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci14: 673–680.
TylsFPalenicekTKaderabekL, et al. (2016) Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol27: 309–320.
71.
VaidyaVAMarekGJAghajanianGK, et al. (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci17: 2785–2795.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
